SNY vs. TEM: Sanofi vs. Tempus AI Stock Comparison

Company Profile

Sanofi (SNY) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but SNY is classified in Pharmaceuticals while TEM is classified in Life Sciences Tools & Services.

Sanofi (SNY) carries decades of public-market history since July 1, 2002, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the SNY side.

Tempus AI (TEM) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) has a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, while Sanofi (SNY) is defensive at 0.28 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Sanofi (SNY) reports 5.72%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Sanofi (SNY) reports 8.20%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Sanofi (SNY) reports 30.89%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Sanofi (SNY) at 5.49% is closer to the peer norm — faster top-line expansion for TEM.

Only one side can be read here: Sanofi (SNY) reports EPS growth of 39.43%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while Sanofi (SNY) at 1.12 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SNY.

Sanofi (SNY) at 0.27 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither Sanofi (SNY) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Tempus AI (TEM) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Sanofi (SNY) trades at 23.40 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Tempus AI (TEM) at 9.19 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile relative to book while Tempus AI (TEM) at 27.66 prices above its industry range — a wide valuation gap against assets.

Valuation Metrics